Prime Medicine, Inc.
PRME · Biological Products, (No Diagnostic Substances) · 180.6M shares · +256%/yr ↑ dilution · EDGAR filings ↗
Reference price $3.30 · est. market cap ~$596M — last insider purchase, 2025-08-01 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — gene-editing clinical, heavy burn ($167M), funded.
Strengths
- Liquidity — current ratio 4.8 (52nd)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Going concern• Because our existing cash, cash equivalents, and investments will not be sufficient to fund our operations, as currently planned, for more than one year beyond the filing date of this Annual Report
- Net lossNet loss (net margin -4342.4%)
- Cash burnNegative free cash flow (-167.1M)
- Chronic dilutionShare count +256%/yr over 3y (dilution, book value/share -99%)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Exec changeRecent 8-K item 5.02 8-K ↗
- Revenue declineRevenue -31.6% YoY
- Notable holderHeld by 6 notable fund(s): STATE STREET CORP, ARK Investment Management LLC, FMR LLC +3 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-4498.1%
Net margin
-4342.4%
Return on equity
-166.4%
Return on assets
-58.7%
Revenue growth (QoQ)
-31.6%
Current ratio
4.8×
Free cash flow
-$167M
EBITDA
-$201M
Tangible book value
$121M
Cash & investments
$178M
Cash runway
4q
Stock comp / revenue
631.9%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-08-01 | NELSEN ROBERT | Buy | 3.0M | $3.30 |
| 2025-08-01 | ARCH Venture Partners XII, LLC | Buy | 3.0M | $3.30 |
| 2025-08-01 | ARCH Venture Partners X, LLC | Buy | 3.0M | $3.30 |
| 2025-08-01 | GV 2021 GP, L.L.C. | Buy | 1.5M | $3.30 |
| 2025-06-30 | Liu David R. | Buy | 21K | $2.52 |
| 2025-06-23 | Liu David R. | Buy | 21K | $2.16 |
| 2025-06-16 | Liu David R. | Buy | 21K | $1.49 |
| 2025-06-11 | Liu David R. | Buy | 21K | $1.60 |
| 2025-05-21 | LEE ANN L. | Buy | 100K | $1.13 |
| 2025-05-21 | Reine Allan | Buy | 125K | $1.18 |
| 2025-05-20 | Brudnick Richard | Buy | 20K | $1.19 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06559176 ↗ | A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ) Chronic Granulomatous Disease, Granulomatous Disease, Chronic | PHASE1/PHASE2 | Enrolling By Invitation | 2030-01-01 |
| NCT07226622 ↗ | Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial Wilson Disease | — | Active Not Recruiting | 2027-12-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-08 | 2026-06-05 | 0001628280-26-041543 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001628280-26-031719 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001628280-26-031726 ↗ |
| 8-K | 2026-04-16 | 2026-04-07 | 0001628280-26-025372 ↗ |
| 10-K | 2026-03-03 | 2025-12-31 | 0001628280-26-013569 ↗ |
| 8-K | 2026-03-03 | 2026-03-03 | 0001628280-26-013565 ↗ |
| 8-K | 2026-01-12 | 2026-01-12 | 0001628280-26-001773 ↗ |
| 10-Q | 2025-11-07 | 2025-09-30 | 0001628280-25-050422 ↗ |
| 8-K | 2025-11-07 | 2025-11-07 | 0001628280-25-050415 ↗ |
| 8-K | 2025-09-08 | 2025-09-08 | 0001894562-25-000056 ↗ |
| 8-K | 2025-08-07 | 2025-08-07 | 0001628280-25-038617 ↗ |
| 10-Q | 2025-08-07 | 2025-06-30 | 0001628280-25-038619 ↗ |